Home › Japan pharmaceutical market › Daratumumab (Genetical Recombination) / Vorhyaluronidase Alfa (Genetical Recombination)
Japan market size · Molecule
ダラツムマブ（遺伝子組換え）・ボルヒアルロニダーゼ アルファ（遺伝子組換え） · その他の腫瘍用薬
The prescription value of Daratumumab (Genetical Recombination) / Vorhyaluronidase Alfa (Genetical Recombination) in Japan was an estimated ¥67.8 billion in FY2024 (April 2024–March 2025), 3.6% of other antineoplastic agents. Value changed +13.9% year on year and +44.3% a year on average over the last three years. It is supplied by 1 companies under 1 products (all shipping normally).
Hover or tap a year for the values. Related drugs are shown as an index so that growth can be compared.
Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.
Contact usValues are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.
